<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pulmonary hypertension in adults with congenital heart disease: General management and prognosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pulmonary hypertension in adults with congenital heart disease: General management and prognosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pulmonary hypertension in adults with congenital heart disease: General management and prognosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Heidi M Connolly, MD, FACC, FASE
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert P Frantz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John K Triedman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 29, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H616028383">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 3 to 10 percent of patients with congenital heart disease (CHD) develop pulmonary hypertension (termed pulmonary hypertension-congenital heart disease [PH-CHD]) [
         <a href="#rid1">
          1,2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Epidemiology'
         </a>
         .)
        </p>
        <p>
         The general management and prognosis for adults with PH-CHD are discussed here. The clinical manifestations and diagnosis, issues related to contraception and pregnancy, and disease-specific management of PH-CHD are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/139770.html" rel="external">
          "Pulmonary hypertension in adults with congenital heart disease: Disease-specific management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2389832410">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension (PH)
         </strong>
         – PH is defined as a mean pulmonary artery pressure (PAP) &gt;20 mmHg at rest [
         <a href="#rid3">
          3
         </a>
         ]. This threshold for diagnosis is lower than the previously used threshold of ≥25 mmHg [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary hypertension-congenital heart disease (PH-CHD)
         </strong>
         – Patients with PH-CHD have a variety of types of PH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ). In patients with PH-CHD, PH is commonly, but not always, caused by CHD. The most common type of PH-CHD is congenital shunt-related pulmonary arterial hypertension (PAH). (See
         <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Classification'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/105507.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Clinical manifestations and diagnosis", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary arterial hypertension
         </strong>
         – PAH is a type of PH diagnosed by demonstration of a mean PAP ≥20 mmHg and a pulmonary vascular resistance (PVR) ≥2 Wood units (WU), along with exclusion of other types of PH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 1
         </a>
         ). Treatment is reserved for PAH with PVR ≥3 WU since there are insufficient data to support treatment for PVR of 2 to 3 WU. Severe PAH is identified by a PVR ≥5 WU [
         <a href="#rid5">
          5
         </a>
         ]. PAH associated with CHD (PAH-CHD) is one of many types of PAH. Eisenmenger syndrome is the most severe form of congenital shunt-related PAH. (See
         <a class="medical medical_review" href="/z/d/html/8249.html" rel="external">
          "Clinical features and diagnosis of pulmonary hypertension of unclear etiology in adults", section on 'Group 1: Pulmonary arterial hypertension'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eisenmenger syndrome
         </strong>
         – This disorder is the most severe form of congenital shunt-related PAH and is characterized by the triad of large intra- or extracardiac congenital defect with an initial systemic-to-pulmonary shunt (ventricular, atrial, or great artery  (
         <a class="graphic graphic_table graphicRef55944" href="/z/d/graphic/55944.html" rel="external">
          table 2
         </a>
         )), PAH with shunt reversal (right-to-left) or bidirectional shunting, and resulting hypoxemia with cyanosis  (
         <a class="graphic graphic_figure graphicRef52487 graphicRef70502" href="/z/d/graphic/52487.html" rel="external">
          figure 1A-B
         </a>
         ) [
         <a href="#rid6">
          6,7
         </a>
         ]. The pulmonary arterial disease in Eisenmenger syndrome is caused by increased pulmonary blood flow and/or elevated PAP.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H686330292">
         <span class="h1">
          GENERAL APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PH-CHD should ideally receive clinical care in centers that have shared expertise and training in CHD and PH [
         <a href="#rid8">
          8
         </a>
         ]. These centers provide the optimal combination of clinical expertise, facilities for advanced diagnosis and therapy, structured care, and access to new and evolving therapies.
        </p>
        <p>
         General care of patients with PH-CHD includes management of issues related to the intracardiac shunt, cyanotic heart disease, PH, and Eisenmenger syndrome. Patient education, behavioral modifications, and awareness of potential medical risk factors are important aspects of management [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1962767124">
         <span class="h1">
          ROUTINE FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following sections describe routine follow-up for adults with PH-CHD. If there is a change in symptoms or functional status, additional clinical assessment and testing are performed.
        </p>
        <p class="headingAnchor" id="H3161335791">
         <span class="h2">
          Clinical follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CHD and pulmonary arterial hypertension (PAH) should be seen by a PH-CHD trained clinician(s) at least yearly. Key components of follow-up include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication review
         </strong>
         – All medication changes should be reviewed for potential effect on the systemic blood pressure, loading conditions, intravascular shunting, and renal or hepatic perfusion or function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation of functional status
         </strong>
         – This includes reviewing the patient's history to assess New York Heart Association (NYHA) functional class  (
         <a class="graphic graphic_table graphicRef120580" href="/z/d/graphic/120580.html" rel="external">
          table 3
         </a>
         ) and an exercise test for individuals who are able to exercise. (See
         <a class="local">
          'Routine tests'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Assessment of complications
         </strong>
         – Complications of PH include pulmonary artery thrombosis and right heart failure. (See
         <a class="local">
          'Pulmonary artery thrombosis management'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Complications of cyanotic congenital heart disease include endocarditis, bleeding, erythrocytosis, cholelithiasis, hyperuricemia/gout, neurologic complications, pheochromocytoma, and paraganglioma. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Counseling
         </strong>
         – Patients with PH-CHD should be counseled to avoid conditions associated with high risk, such as pregnancy and volume depletion. (See
         <a class="local">
          'Conditions and procedures to avoid'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with PH-CHD should also be advised to seek prompt attention for medical problems including arrhythmias and infections and to ensure that their PH-CHD care team is notified before they undergo any procedures. Ideally, surgical procedures should be done at referral centers with close follow-up by PH-CHD team. (See
         <a class="local">
          'Management of procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4039673489">
         <span class="h2">
          Routine tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Routine testing is based upon the severity of PH and the patient’s functional status. Cardiac imaging studies are compared with prior studies (including an initial baseline study) using the same imaging modality.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For patients with PH-CHD with mild or moderate PH and NYHA functional class ≤III symptoms
         </strong>
         – This group includes patients with PAH with pulmonary vascular resistance (PVR) ≥3 but &lt;5 Wood units (WU). Routine follow-up with a PH-CHD trained clinician is suggested at 6- to 12-month intervals including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          At each visit
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pulse oximetry with and without supplemental oxygen therapy. Oxygen-responsive hypoxemia should be investigated.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Exercise test (six-minute walk test or submaximal cardiopulmonary exercise test).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Yearly
         </strong>
         –
         <strong>
         </strong>
         Electrocardiogram (ECG) and transthoracic echocardiogram (TTE) are performed yearly. TTE may be deferred if deemed unnecessary due to performance of cardiovascular magnetic resonance [CMR] imaging).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          As needed
         </strong>
         – Additional tests such as CMR and cardiac catheterization are performed as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For patients with PH-CHD with severe PH or NYHA functional class IV symptoms
         </strong>
         – This group includes patients with NYHA functional class IV symptoms, severe PH (including those with PAH with PVR ≥5 WU), or Eisenmenger syndrome. Routine follow-up is suggested at three- to six-month intervals with testing as above with the addition of the following laboratory tests: hemoglobin, platelet count, iron studies, creatinine, and uric acid. These patients should also receive review by the transplant team, if they are potential candidates, and/or the palliative care team. (See
         <a class="medical medical_review" href="/z/d/html/139770.html" rel="external">
          "Pulmonary hypertension in adults with congenital heart disease: Disease-specific management", section on 'Transplantation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H158043282">
         <span class="h1">
          GENERAL MEASURES
         </span>
        </p>
        <p class="headingAnchor" id="H2105375846">
         <span class="h2">
          Oxygen therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oxygen therapy is used only in selected patients with PH-CHD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term oxygen therapy
         </strong>
         – Oxygen therapy may improve symptoms but has not been shown to modify survival [
         <a href="#rid9">
          9,10
         </a>
         ]. The use of supplemental oxygen therapy, either nocturnal or continuous, is suggested in patients with hypoxemia in whom it produces a consistent increase in arterial oxygen saturation and reduces symptoms [
         <a href="#rid9">
          9
         </a>
         ]. Oxygen may decrease pulmonary vasoconstriction; it is recommended in select patients with hemodynamic confirmation of improved pulmonary blood flow with oxygen therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Oxygen for altitude
         </strong>
         – Supplemental oxygen is suggested for air travel or ascent to altitude for patients with class III or IV symptoms related to PH-CHD and those with hypoxemia (peripheral arterial oxygen saturation &lt;90 percent). This recommendation is based on the risk of altitude-related hypoxia and the resultant physiologic effects, which include hyperventilation, increased heart rate, and chronic increased red cell production in an attempt to maintain arterial blood oxygen content at or above sea level values [
         <a href="#rid11">
          11
         </a>
         ].
         <sup>
         </sup>
         Hypoxic pulmonary vasoconstriction and vascular remodeling place an increased pressure load on the right ventricle. Response to altitude or travel-related hypoxia depends on the rate of ascent to altitude, the severity and duration of exposure, and the underlying disease severity [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1543.html" rel="external">
          "Approach to patients with heart disease who wish to travel by air or to high altitude"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1033922927">
         <span class="h2">
          Anticoagulation
         </span>
        </p>
        <p class="headingAnchor" id="H2385057270">
         <span class="h3">
          Indications for anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We reserve anticoagulant treatment for patients with PH-CHD who have a specific indication for anticoagulation, such as pulmonary artery thrombosis [
         <a href="#rid13">
          13
         </a>
         ], confirmed paradoxical embolism, and those with atrial fibrillation [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         Oral anticoagulant treatment in PH-CHD/Eisenmenger syndrome is controversial, with limited evidence available to guide use. Most clinicians who care for complex congenital heart disease patients recommend anticoagulation for Eisenmenger patients with pulmonary arterial thrombosis. However, there are no data to support routine anticoagulation in this patient population. Although there is an important risk of pulmonary artery thrombosis and stroke reported in patients with Eisenmenger syndrome, anticoagulation can provoke bleeding, including hemoptysis. In addition, anticoagulation in cyanotic patients requires citrate adjustment for accurate international normalized ratio (INR) quantification. Improper INR monitoring has led to deaths in patients with Eisenmenger syndrome treated with
         <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">
          warfarin
         </a>
         . The risk-benefit ratio must be assessed on a case-by-case basis. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults", section on 'Pitfalls in laboratory testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2785214453">
         <span class="h3">
          Pulmonary artery thrombosis management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary arterial thrombosis among adults with Eisenmenger syndrome is a common cause for clinical deterioration and is associated with older age, biventricular dysfunction, and slow pulmonary artery blood flow. It does not appear to be related to the degree of cyanosis or coagulation abnormalities [
         <a href="#rid14">
          14
         </a>
         ]. In two reports, significant in situ proximal pulmonary artery thrombus was seen in 21 and 29 percent of patients with Eisenmenger syndrome [
         <a href="#rid15">
          15,16
         </a>
         ]. Some patients may also have distal arterial thrombosis [
         <a href="#rid16">
          16
         </a>
         ]. Pulmonary parenchymal findings include embolic infarcts [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Structural and functional changes in the pulmonary vasculature probably play a role in the development of in situ pulmonary artery thrombosis. The large arteries dilate and become aneurysmal, contributing to stasis and thrombus formation [
         <a href="#rid17">
          17
         </a>
         ]. In addition, endothelial damage due to increased shear stress, increased blood viscosity, and hypoxemia may all contribute to a prothrombotic state [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         The consequences of pulmonary artery thrombosis in Eisenmenger syndrome vary. Massive thrombosis can lead to death and augmented right-to-left shunts by increasing flow resistance [
         <a href="#rid15">
          15
         </a>
         ], while the presence of more distal thrombosis and intraparenchymal infarction raises concern that pulmonary artery thrombosis may contribute to the progression of pulmonary vascular disease [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2211683316">
         <span class="h2">
          Prevention of endocarditis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients should maintain good oral hygiene to lessen the magnitude of transient bacteremias associated with routine oral care and reduce the risk of periodontal disease. Oral and other bacterial infections should be treated promptly. Antimicrobial prophylaxis for bacterial endocarditis is indicated for patients at high risk for adverse outcomes with infective endocarditis, including those with any of the following: unrepaired cyanotic CHD; completely repaired congenital heart defect with prosthetic material or device, during the first six months after surgical or transcatheter placement; repaired CHD with residual defect at the site or adjacent to the site of a prosthetic patch or prosthetic device; or a prosthetic heart valve. (See
         <a class="medical medical_review" href="/z/d/html/2147.html" rel="external">
          "Prevention of endocarditis: Antibiotic prophylaxis and other measures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1480654870">
         <span class="h2">
          Immunizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Individuals with PH-CHD should receive appropriate immunizations, including pneumococcal vaccine, coronavirus 2019 (COVID-19) vaccine, and annual influenza vaccine. (See
         <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">
          "Standard immunizations for nonpregnant adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">
          "Pneumococcal vaccination in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">
          "COVID-19: Vaccines"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">
          "Seasonal influenza vaccination in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3560801672">
         <span class="h2">
          Management of cyanotic CHD
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management for patients with Eisenmenger syndrome includes measures for management of cyanotic CHD, including addressing the following issues, which are discussed separately (see
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults"
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phlebotomy
         </strong>
         – In patients with cyanotic heart disease, phlebotomy is suggested only with expert consultation and in combination with volume repletion for relief of hyperviscosity symptoms [
         <a href="#rid13">
          13
         </a>
         ], such as blurred vision, neurologic symptoms, confusion, and heart failure. Repeated routine phlebotomies are avoided because of the risk of iron depletion, decreased oxygen-carrying capacity, and stroke [
         <a href="#rid8">
          8,9,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults", section on 'Erythrocytosis and relative anemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of iron deficiency
         </strong>
         – Iron deficiency with relative anemia should be carefully treated with iron supplementation. Although there are no specific data regarding timing, we institute iron supplementation in anemic patients with evidence of iron deficiency (ie, low ferritin plasma levels) when the mean corpuscular volume is less than 82, since microspherocytes may increase cerebrovascular risk [
         <a href="#rid21">
          21
         </a>
         ]. Iron should be discontinued when the hematocrit begins to rise, usually within 7 to 10 days. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults", section on 'Erythrocytosis and relative anemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7148.html" rel="external">
          "Treatment of iron deficiency anemia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3758068113">
         <span class="h1">
          CONDITIONS AND PROCEDURES TO AVOID
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are a number of conditions or procedures that are associated with increased risk in patients with PH-CHD, particularly those with Eisenmenger syndrome, and should therefore be avoided; these include volume depletion, isometric exercise, high altitude, and pregnancy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2296795168">
         <span class="h2">
          Volume depletion or systemic vasodilation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the risk of decompensation with volume depletion or systemic vasodilation (eg, excessive heat, hot tubs, excessive alcohol), euvolemia should be maintained, and precipitants of systemic vasodilation should be avoided in patients with PH-CHD, particularly with Eisenmenger syndrome [
         <a href="#rid23">
          23
         </a>
         ]. A fall in systemic vascular resistance can result in an increase in right-to-left shunt with subsequent reduction in cerebral blood flow and possible cardiovascular collapse due to reduced cardiac output. (See
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults", section on 'Erythrocytosis and relative anemia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3492731335">
         <span class="h2">
          Excessive exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with moderate or severe PH-CHD, with a mean pulmonary artery pressure &gt;25 mmHg, are counseled to avoid all competitive athletics, with the possible exception of low-intensity (class IA) sports  (
         <a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. Complete evaluation and clinician guidance of exercise training (exercise prescription) are recommended prior to athletic participation; isometric exercise should generally be avoided. Nonisometric and low-intensity activities are encouraged. Benefits of regular exercise include improved walking distance, peak oxygen consumption, quality of life, and functional class; thus, nonmaximal physical activity should be encouraged [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1815600476">
         <span class="h2">
          High altitude
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PH-CHD should
         <strong>
          avoid
         </strong>
         high altitude (particularly an elevation greater than 5000 feet above sea level) because the low oxygen tension leads to pulmonary vasoconstriction and further desaturation [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         Limited data suggest that it is safe for Eisenmenger patients to travel in commercial airlines as long as the airplanes are adequately pressurized [
         <a href="#rid25">
          25,26
         </a>
         ]. Supplemental oxygen should be available, although its efficacy is unproven. (See
         <a class="medical medical_review" href="/z/d/html/1448.html" rel="external">
          "Evaluation of patients for supplemental oxygen during air travel"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1982265269">
         <span class="h2">
          Endocardial pacing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocardial pacemaker or implantable cardioverter-defibrillator leads are generally avoided in patients with PH-CHD with persistent intracardiac shunting given the increased risk of systemic thromboembolism. Alternative access for pacing and/or defibrillation (epicardial or subcutaneous) should be considered on an individual basis. (See
         <a class="medical medical_review" href="/z/d/html/941.html" rel="external">
          "Permanent cardiac pacing: Overview of devices and indications", section on 'Types of permanent pacemaker systems'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2196344916">
         <span class="h2">
          Air emboli
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the risk of a paradoxical air embolism in Eisenmenger patients (and lesser risk in patients with only transient right-to-left shunts), air bubbles should be excluded from intravenous tubing by meticulous intravenous line care and use of air filters [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8263.html" rel="external">
          "Air embolism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1650556375">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The high maternal and fetal risks of pregnancy in a patient with PH-CHD (particularly with Eisenmenger syndrome), counseling, contraception, and management of pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/139887.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Pregnancy and contraception"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2228106237">
         <span class="h1">
          MANAGEMENT OF PROCEDURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any surgical procedure, even if relatively minor, is potentially life-threatening in patients with PH-CHD, particularly those with Eisenmenger syndrome, and is associated with a perioperative mortality of up to 19 percent [
         <a href="#rid27">
          27
         </a>
         ]. The risk is especially high when surgery is performed on an emergency basis, is lengthy, and is associated with hemodynamic instability necessitating large-volume fluid resuscitation [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         All elective invasive procedures and procedures requiring sedation (such as cardioversion, cardiac catheterization, and endoscopy) should be performed only at a center with expertise in the management of PH-CHD and Eisenmenger syndrome [
         <a href="#rid20">
          20
         </a>
         ]. In emergency or urgent situations in which transportation is not feasible, caregivers in centers with expertise in the care of patients with Eisenmenger syndrome should be consulted throughout care. A multidisciplinary approach is imperative and should include involvement of a senior cardiac anesthesiologist, an experienced surgeon, and a cardiologist experienced with the care of patients with PH-CHD including Eisenmenger syndrome [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Key management principles include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Optimize hematocrit
         </strong>
         – The preoperative clinical assessment should include routine laboratory evaluation. The ideal hematocrit for the Eisenmenger patient undergoing noncardiac surgery is uncertain, but is likely to be less than 65 percent. In patients with higher values, preoperative phlebotomy may improve the coagulation status. The phlebotomized blood should be preserved for potential transfusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After surgery, patients should be transfused if the hematocrit is inappropriately low for the oxygen saturation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintain volume
         </strong>
         – Intravascular volume depletion should be avoided before, during, and after surgery. Preprocedural hydration is generally indicated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitor
         </strong>
         – Intraoperative and early postoperative cardiac rhythm monitoring is suggested. In most cases, an intraarterial line and pulse oximetry provide sufficient information regarding systemic hemodynamics and oxygenation. Pulmonary artery catheter monitoring is seldom necessary and should be avoided, if possible, because of a high potential for hemorrhagic and other complications [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maintain blood pressure
         </strong>
         – A fall in systemic blood pressure should be avoided to prevent an increase in the right-to-left shunt. If the systemic blood pressure does fall, it is generally better managed with volume repletion than vasopressors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoid air emboli
         </strong>
         – Precautions should be taken against paradoxical air emboli. (See
         <a class="local">
          'Air emboli'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevent deep venous thrombosis
         </strong>
         – Early ambulation and perioperative deep venous thrombosis prophylaxis are recommended. (See
         <a class="medical medical_review" href="/z/d/html/1339.html" rel="external">
          "Prevention of venous thromboembolic disease in adult nonorthopedic surgical patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2656642358">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adults with PH-CHD face a higher risk of early mortality compared with the broader population of adults with CHD. This was illustrated by a study of 6933 adults with CHD in the Dutch CONgenital CORvitia (CONCOR) registry [
         <a href="#rid31">
          31
         </a>
         ]. The median age of death among adults with CHD was 48.8 years, and presence of PH predicted a threefold increase in all-cause mortality after adjustment for age, sex, and CHD severity [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         The mean age at death of patients with Eisenmenger syndrome has been reported to be 37 years or less, although the clinical course varies among individuals and these data precede routine use of pulmonary vasodilators. Although some patients with Eisenmenger syndrome survive into their 60s and beyond [
         <a href="#rid17">
          17,32-35
         </a>
         ], survival is generally limited, as illustrated by a systematic review that included 12 studies of 1131 patients with Eisenmenger syndrome not treated with advanced therapy for pulmonary hypertension [
         <a href="#rid36">
          36
         </a>
         ]. The analysis was adjusted for immortal time bias found in many reports. The mean age was 30 years old and the adjusted 10-year mortality rates ranged between 30 and 40 percent. Although mortality rates in the 1950s and 1960s were worse, similar mortality rates were observed in patients studied from the 1970s to the 2000s.
        </p>
        <p>
         Prognosis in patients with PH-CHD depends largely on the impact of PH on cardiovascular status. Fatal complications of Eisenmenger syndrome include progressive cardiovascular disease and heart failure, sudden cardiac death, and intrapulmonary hemorrhage due to rupture of a major vessel [
         <a href="#rid17">
          17,32,37
         </a>
         ].
        </p>
        <p>
         Among patients with PH-CHD, prognostic features include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical characteristics
         </strong>
         – Among patients with Eisenmenger syndrome, worse functional class is a predictor of mortality [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with Eisenmenger syndrome with complex CHD may have earlier clinical deterioration (eg, mean age 19 versus 27 years [
         <a href="#rid32">
          32
         </a>
         ]) and shorter survival (eg, mean age 26 versus 33 years [
         <a href="#rid32">
          32
         </a>
         ]) than those with simple CHD. In a series of 171 patients with Eisenmenger syndrome, median survival was reduced by approximately 20 years in those with simple underlying lesions and by approximately 40 years in those with complex lesions compared with healthy individuals [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hemoptysis is common among patients with Eisenmenger syndrome (20 percent in one series) but may not affect prognosis [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical examination
         </strong>
         – Findings associated with poor prognosis include signs of reduced cardiac output (such as tachycardia, low pulse pressure and hypotension) and features of right heart dysfunction (such as venous pressure elevation) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Electrocardiographic and laboratory findings
         </strong>
         – Among patients with Eisenmenger syndrome, clinical arrhythmia, longer QRS duration, and longer QTc interval are associated with increased risk of mortality [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lower oxygen saturation at rest [
         <a href="#rid35">
          35
         </a>
         ], low serum albumin, and low potassium levels are also associated with adverse prognosis [
         <a href="#rid34">
          34
         </a>
         ]. Elevated serum natriuretic peptide level (eg, B-type natriuretic peptide) was associated with mortality risk in some studies of patients with PH-CHD [
         <a href="#rid38">
          38,39
         </a>
         ] but was not an independent predictor of mortality in a multivariate analysis [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echocardiographic findings
         </strong>
         – Echocardiographic features of advanced PH (including right heart dysfunction, dilated inferior vena cava, and the presence of pericardial effusion) are associated with adverse prognosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among patients with Eisenmenger syndrome, the mortality risk is higher with a pretricuspid shunt and presence of pericardial effusion [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cause of PH
         </strong>
         – Among patients with PH-CHD, the worst survival has been reported in patients with group 1 pulmonary arterial hypertension (PAH) after defect repair or with small/coincidental defects [
         <a href="#rid40">
          40
         </a>
         ]. Patients with PAH with small/coincidental defects as well as some patients who develop PAH after defect repair may have PAH unrelated to CHD (and their clinical characteristics are similar to idiopathic PAH).
        </p>
        <p>
        </p>
        <p>
         The prognosis for patients with Eisenmenger syndrome appears to be better than for patients with idiopathic PAH with similar hemodynamics [
         <a href="#rid41">
          41,42
         </a>
         ]. This was illustrated in a report of patients with severe PAH (37 Eisenmenger, 57 idiopathic PAH) [
         <a href="#rid41">
          41
         </a>
         ]. Actuarial survival at one and three years among those not receiving transplants was higher in those with Eisenmenger syndrome (97 versus 77 percent and 77 versus 35 percent, respectively). (See
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         Better survival in patients with Eisenmenger syndrome compared with that in patients with idiopathic PAH may result from preservation of biventricular function in patients with Eisenmenger syndrome, as the right ventricle remains hypertrophied after birth and is therefore better able to accommodate the elevated afterload. The right ventricle is also relieved by the right-to-left shunt, which acts as a "pop-off" valve for the right ventricle [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1855840065">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">
          "Society guideline links: Pulmonary hypertension in adults"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122280.html" rel="external">
          "Society guideline links: Congenital heart disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3980092786">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General approach
         </strong>
         – Patients with pulmonary hypertension associated with congenital heart disease (PH-CHD) should ideally receive clinical care in centers that have shared expertise and training in adult CHD and PH [
         <a href="#rid8">
          8
         </a>
         ].General care includes principles of management of cyanotic heart disease, PH, and Eisenmenger syndrome. (See
         <a class="local">
          'General approach'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/1423.html" rel="external">
          "Medical management of cyanotic congenital heart disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         – Patients with PH-CHD should receive at least yearly routine follow-up including medication review, evaluation of functional status, assessment of complications, counseling, and testing (generally including pulse oximetry, a submaximal exercise test, an ECG, and a transthoracic echocardiogram [TTE]). If there is a change in status, additional clinical assessment is performed. (See
         <a class="local">
          'Routine follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Conditions and procedures to avoid
         </strong>
         – Conditions and procedures that are associated with an increased risk in patients with PH-CHD (particularly those with Eisenmenger syndrome) and should therefore be avoided include volume depletion, isometric exercise, high altitude, endocardial pacing, air emboli, and pregnancy. (See
         <a class="local">
          'Conditions and procedures to avoid'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/139887.html" rel="external">
          "Pulmonary hypertension with congenital heart disease: Pregnancy and contraception"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of procedures
         </strong>
         – Any surgical procedure, even if relatively minor, is potentially life-threatening in patients with PH-CHD, particularly those with Eisenmenger syndrome. (See
         <a class="local">
          'Management of procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         All elective invasive procedures and procedures requiring sedation (such as cardioversion, cardiac catheterization, and endoscopy) should be performed at a center with expertise in the management of PH-CHD. In emergency or urgent situations in which transportation is not feasible, caregivers in centers with expertise in the care of patients with Eisenmenger syndrome should be consulted throughout care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis
         </strong>
         – The prognosis for patients with PH-CHD depends on the cause of PH-CHD, the severity of PH, clinical features (particularly cardiovascular status), and response to therapy. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes. J Am Coll Cardiol 2011; 58:538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Riel AC, Schuuring MJ, van Hessen ID, et al. Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 2014; 174:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 2021; 42:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins WE. The remarkable right ventricle of patients with Eisenmenger syndrome. Coron Artery Dis 2005; 16:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins WE, Waggoner AD. Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome. Am J Cardiol 2002; 89:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019; 139:e698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandoval J, Aguirre JS, Pulido T, et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am J Respir Crit Care Med 2001; 164:1682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grocott MP, Martin DS, Levett DZ, et al. Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med 2009; 360:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkins MR, Ghofrani HA, Weissmann N, et al. Pathophysiology and treatment of high-altitude pulmonary vascular disease. Circulation 2015; 131:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broberg CS, Ujita M, Prasad S, et al. Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity. J Am Coll Cardiol 2007; 50:634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perloff JK, Hart EM, Greaves SM, et al. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol 2003; 92:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silversides CK, Granton JT, Konen E, et al. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol 2003; 42:1982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niwa K, Perloff JK, Kaplan S, et al. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J Am Coll Cardiol 1999; 34:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altman R, Scazziota A, Rouvier J, et al. Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 1996; 19:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hassell KL. Altered hemostasis in pulmonary hypertension. Blood Coagul Fibrinolysis 1998; 9:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart disease. J Am Coll Cardiol 1996; 28:768.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stout KK, Daniels CJ, Aboulhosn JA, et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73:e81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007; 115:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart 2007; 93:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harinck E, Hutter PA, Hoorntje TM, et al. Air travel and adults with cyanotic congenital heart disease. Circulation 1996; 93:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vongpatanasin W, Brickner ME, Hillis LD, Lange RA. The Eisenmenger syndrome in adults. Ann Intern Med 1998; 128:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ammash NM, Connolly HM, Abel MD, Warnes CA. Noncardiac surgery in Eisenmenger syndrome. J Am Coll Cardiol 1999; 33:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham TP Jr, Driscoll DJ, Gersony WM, et al. Task Force 2: congenital heart disease. J Am Coll Cardiol 2005; 45:1326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson S. Pulmonary artery catheters in Eisenmenger's syndrome: many risks, few benefits. Anesthesiology 1983; 58:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verheugt CL, Uiterwaal CS, van der Velde ET, et al. Mortality in adult congenital heart disease. Eur Heart J 2010; 31:1220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur Heart J 1998; 19:1845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Warnes CA, Boger JE, Roberts WC. Eisenmenger ventricular septal defect with prolonged survival. Am J Cardiol 1984; 54:460.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J 2006; 27:1737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempny A, Hjortshøj CS, Gu H, et al. Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study. Circulation 2017; 135:1432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diller GP, Kempny A, Inuzuka R, et al. Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience. Heart 2014; 100:1366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saha A, Balakrishnan KG, Jaiswal PK, et al. Prognosis for patients with Eisenmenger syndrome of various aetiology. Int J Cardiol 1994; 45:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kücükoglu SM, Kaymaz C, Alehan D, et al. Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES). Pulm Circ 2021; 11:20458940211024206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiu SN, Lu CW, Lin MT, et al. Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease. J Am Heart Assoc 2022; 11:e022596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. Eur Heart J 2014; 35:716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant 1996; 15:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden AM, Robert RC, Kriett JM, et al. Primary diagnosis predicts prognosis of lung transplant candidates. Transplantation 1993; 55:1048.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 119400 Version 10.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21777753" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Diagnosis of pulmonary hypertension in the congenital heart disease adult population impact on outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24794056" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545968" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Haemodynamic definitions and updated clinical classification of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24355641" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Definitions and diagnosis of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32860028" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : 2020 ESC Guidelines for the management of adult congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15654195" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The remarkable right ventricle of patients with Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11779519" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Severe pulmonary hypertension without right ventricular failure: the unique hearts of patients with Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30586767" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11719310" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Nocturnal oxygen therapy in patients with the Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19129527" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Arterial blood gases and oxygen content in climbers on Mount Everest.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25666980" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pathophysiology and treatment of high-altitude pulmonary vascular disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26320113" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17692749" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pulmonary arterial thrombosis in eisenmenger syndrome is associated with biventricular dysfunction and decreased pulmonary flow velocity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12860221" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14662263" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Pulmonary thrombosis in adults with Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10400015" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8818435" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Coagulation and fibrinolytic parameters in patients with pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9622208" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Altered hemostasis in pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18997169" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8772770" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cerebrovascular events in adult patients with cyanotic congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30121239" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325254" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Pulmonary vascular disease in adults with congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26542660" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 4: Congenital Heart Disease: A Scientific Statement From the American Heart Association and American College of Cardiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17164484" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adult patients with Eisenmenger syndrome report flying safely on commercial airlines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8548899" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Air travel and adults with cyanotic congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9556469" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The Eisenmenger syndrome in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9935034" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Noncardiac surgery in Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15837282" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Task Force 2: congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6859598" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pulmonary artery catheters in Eisenmenger's syndrome: many risks, few benefits.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20207625" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mortality in adult congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9886728" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Eisenmenger syndrome. Factors relating to deterioration and death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6465038" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Eisenmenger ventricular septal defect with prolonged survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16793921" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27979875" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Predictors of Death in Contemporary Adult Patients With Eisenmenger Syndrome: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25099652" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7960265" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prognosis for patients with Eisenmenger syndrome of various aetiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34211699" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pulmonary arterial hypertension associated with congenital heart disease: lessons learnt from the large Turkish Nationwide Registry (THALES).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35285668" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pulmonary Hypertension in Adult Congenital Heart Disease in Asia: A Distinctive Feature of Complex Congenital Heart Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23455361" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8820089" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8497879" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Primary diagnosis predicts prognosis of lung transplant candidates.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
